Heron Therapeutics preliminary Q4 2025 net revenue $40.5M; full-year $154.9M

HERON THERAPEUTICS, INC. /DE/

2025-FY EPS reported -$0.12 revenue$154,904,000

Q4 2025 net revenue approximately $40.5M, driven by Acute Care franchise momentum.
Full-year 2025 net revenue approximately $154.9M (preliminary, unaudited).
ZYNRELEF net revenue $12.5M in Q4, up ~35% vs Q3 2025, largest product growth.
APONVIE net revenue $3.8M, CINVANTI $22.9M, SUSTOL $1.3M in Q4 2025.
CEO Craig Collard cites continued progress across all aspects of business.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.